NEURORECEPTOR FUNCTION AND PSYCHOPHARMACOLOGIC RESPONSE

References

• Bedford, F. K., Julius, D., & Ingraham, H. A. (1998). Neuronal expression of the 5HT3 serotonin receptor gene requires nuclear factor 1 complexes. Journal of Neuro-science, 18, 6186–6194.
   Google Scholar
• Bezchlibnyk-Butler, K. Z., & Jeffries, J. J. (1997). Clinical handbook of psychotropic drugs. Seattle, WA: Hogrefe & Huber Publishers.
   Google Scholar
• Bielenberg, G. W., & Burkhardt, M. (1990). 5-HTIA agonists: A new therapeutic prin-ciple for stroke treatment. Stroke, 21(Suppl.), 161–163.
   Google Scholar
• Buckley, N. J., Bonner, T. I., Buckley, C. M., & Brann, M. R. (1989). Antagonists binding properties of five cloned muscarinic receptors expressed in CHO-K 1 cells. Molecular Pharmacology, 35,469–476.
   PubMed Web of Science ®Google Scholar
• Calne, D. B. (1993). Treatment of Parkinson's disease. New England Journal of Medicine, 329, 1021–1030.
   PubMed Web of Science ®Google Scholar
• Civelli, 0., Bunzow, J. R., & Grandy, D. K. (1993). Molecular diversity of the dopamine receptors. Annual Review of Pharmacologic Toxicology, 32,281–307.
   Google Scholar
• Coccara, E. G. (1989). Central serotonin and impulsive aggression. British Journal of Psychiatry, /55(Suppl.), 52–62.
   Google Scholar
• Cowen, P. T. (1991). Serotonin receptor subtypes: Implications for psychopharmacology. British Journal of Psychiatry, /59\(suppl 12), 7–14.
   Google Scholar
• Crow, T. (1987) . Two syndromes of schizophrenia as one pole of continuum of psychosis: A concept of the nature of the pathogen and its genomic locus. In F. A. Henn & L. E. DeLisi (Eds.), Handbook of schizophrenia (Vol. 2). Amsterdam: Elseiver.
   Google Scholar
• DiRocco, A., Brannan, T., Prikhojan, A., & Yahr, M. D. (1998). Sertraline induced parkins onism. A case report and an in vivo study of the effect of sertraline in dopamine metabolism. Journal of Neural Transmission, 105, 247–251.
   PubMedGoogle Scholar
• Dubovsky, S. L. (1994). Beyond the serotonin reuptake inhibitors: Rationale for the development of new serotonergic agents. Journal of Clinical Psychiatry, 55(Suppl.), 34–44.
   Google Scholar
• Ereshefsky, L., Tran-Johnson, T. K., & Watanabe, M. D. (1990). Pathophysiologic basis for schizophrenia and the efficacy of antipsychotics. Clinical Pharmacology, 9, 682–707.
   Google Scholar
• Fletcher, S., & Barnes, N. M. (1998). Desperately seeking subunits: Are 5-H3 receptors really homomeric complexes? Trends in Pharmacological Sciences, 19, 212-215. Gerber, P. E., & Lynd, L. D. (1998). Selective serotonin-reuptake inhibitor-induced movement disorders. Annals of Phannacotherapy, 36, 692–698.
   Google Scholar
• Glitz, D. A., & Pohl, R. (1991). 5-HT1A partial agonists: What is their future? Drugs, 41, 11–18.
   Google Scholar
• Grahame-Smith, D. G. (1992). Serotonin in affective disorders. International Clinical Psychophannacology, 6\(Suppl. 4), 5–13.
   PubMedGoogle Scholar
• Guidotti, I., Corda, M. G., Wise, B. C., et al. (1983). GABAergic synapses: Supramolec- ular organization and biochemical regulation. Neurophannacology, 22, 1471-1479. Guttman, M. (1992). Dopamine receptors in Parkinson's disease. Neurologic Clinics, 10, 377–386.
   Google Scholar
• Harrington, M. A., Zhong, P., & Garlow, S. J., et al. (1992). Molecular biology of sero-tonin receptors. Journal of Clinical Psychiatry, 53(Suppl.), 8–27.
   Google Scholar
• Harvey, K. V., & Balon, R. (1995). Clinical implications of antidepressant drug effects on sexual function. Annals of Clinical Psychiatry, 7, 189–201.
   PubMedGoogle Scholar
• Haxhiu, M. A., Erokwu, B., Bhardwaj, V., & Dreshaj, I. A. (1998). The role of the medullary raphe nuclei in regulation of cholinergic outflow to the airway. Journal of the Autonomic Nervous System, 69, 64–71.
   PubMedGoogle Scholar
• Hulme, E. C., Birdsall, N. J., & Buckley, N. J. (1990). Muscarinic receptor subtypes. Annual Review of Pharmacology & Toxicology, 30, 633–673.
   PubMed Web of Science ®Google Scholar
• Jose, P. A., Eisner, G. M., & Felder, R. A. (1998). Renal dopamine receptors in health and hypertension. Pharmacology & Therapeutics, 80, 49–182.
   PubMedGoogle Scholar
• Joyce, J. (1993). The dopamine hypothesis of schizophrenia: Limbic interactions with serotonin and norepinephrine. Psychopharmacology, / /2(Suppl.), S16-S34. Kandel, E. R., Schwartz, J. H., & Jes sell, T. M. (1991). Principles of neural science (3rd ed.). Norwalk, CT: Appleton & Lange.
   Google Scholar
• Kasper, S., Praschak-Rieder, N., Tauscher, J., & Wolf, R. (1997). A risk-benefit assess- ment of mirtazapine in the treatrment of depression. Drug Safety, 17, 251–264. Kapur, S., Zipursky, R., Remington, G., Jones, C., et al. (1997). PET evidence that loxapine is an equipotent blocker of 5-HT2 and D2 receptors: Implications for the therapeutics of schizophrenia. American Journal of Psychiatry, 154, 1525–1529. Keltner, N. L., & Folks, D. G. (1997). Psychotropic drugs. St. Louis, MO: Mosby. Keltner, N. L, Folks, D. G., Palmer, C., & Powers, R. E. (1998). Psychobiological foundations of psychiatric care. St. Louis, MO: Mosby.
   Google Scholar
• Landry, M. J. (1994). Serotonin and impulsivity dyscontrol: Brain chemistry involved in impulse and addictive behavior. Behavioral Health Management, 14, 35-38. Lehne, R. A. (1998). Pharmacology for nursing care (3rd ed.). Philadelphia: Saunders. Leonard, B. E. (1992). Subtypes of serotonin receptors: Biochemical changes and phar- macological consequences. International Journal of Psychopharmacology, 7, 13–21.
   Google Scholar
• Leysen, J. E., Janssen, P. M. F., Schotte, A., & Luyton, W. H. M. L., & Megans, A. A. (1993). Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: Role of 5-HT2 receptors. Psychophannacology, 112(Suppl.), S40–S54.
   Google Scholar
• Lopez-Thor, J. L. (1988). The involvement of serotonin in psychiatric disorders and behaviour. British Journal of Psychiatry, /53\(Suppl. 3), 26–39.
   Google Scholar
• Marsden, C. A., & Kendall, D. A. (1992). Neurochemic al identification of 5-HT receptors subtypes. In C. A. Marsden & D. J. Heal (Eds.), Central serotonin receptors and psychotropic drugs (pp. 17–38). London: Blackwell Scientific Publications.
   Google Scholar
• McKenna, K. E. (1998). Central control of penile erection. International Journal of Impotence Research, /0(Suppl.), 525–534.
   Google Scholar
• Medina, A., Bodick, N., Goldberger, A. L., MacMahon, M., & Lipsitz, L. A. (1997). Effects of central muscarinic-1 receptor stimulation on blood pressure regulation. Hypertension, 29, 828–834.
   PubMedGoogle Scholar
• Meltzer, H. (1989a). Serotonergic dysfunction in depression. British Journal of Psychi-atry, 155 (Suppl. 8), 25–31.
   Google Scholar
• Meltzer, H. Y. (1989b). Clinical studies on the mechanism of action of clozapine: The dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology, 99(Suppl.), S18–S27.
   Google Scholar
• Nemeroff, C. B. (1998). The neurobiology of depression. Scientific American, 278(6): 42–49.
   PubMed Web of Science ®Google Scholar
• Nihart, A. M. (1997). Atypical antipsychotics and the pharmacology of olanzapine. Journal of the American Psychiatric Nurses Association, 3, S2–S7.
   Google Scholar
• Perry, C. M., & Markham, A. (1998). Sumatriptan: An updated review of its use in migraine. Drugs, 55,889–922.
   PubMed Web of Science ®Google Scholar
• Piercey, M. F. (1998). Pharmacology of pramipexole, a dopamine D3-preferring ago-nist useful in treating Parkinson's disease. Clinical Neurophannacology, 21, 141–151.
   PubMed Web of Science ®Google Scholar
• Preskorn, S. H. (1994). Update on antidepressant therapy. Journal of Clinical Psychiatry, 55 (Suppl . A), 3–5.
   Google Scholar
• Roth, B. L., Ciaranello, R. D., & Meltzer, H. Y. (1992). Binding of typical and atypical antipsychotic agents to transiently expressed 5-HT1c receptors. Journal of Pharma-cology & Experimental Therapeutics, 260, 1361–1365.
   PubMed Web of Science ®Google Scholar
• Seeman, P. (1990). Atypical neuroleptics: Role of multiple receptors, endogenous dopa-mine, and receptor linkage. Acta Psychiatrica Scandinavica, 82\(Suppl. 348), 14–20.
   PubMedGoogle Scholar
• Seeman, P., Bzowej, N. H., Guan, H. C., Bergeron, C., et al. (1987). Human brain Di and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's disease. Neuropsychopharmacology, 1, 5–15.
   PubMedGoogle Scholar
• Seeman, P., Guan, H. C., & Van Tol, H. H. M. (1993). Dopamine D4 receptors elevated in schizophrenia. Nature, 365, 441–445.
   Google Scholar
• Seeman, P., & van Tol, H. H. M. (1994). Dopamine receptor pharmacology. Trends in Pharmacological Science, 15(7), 64–70.
   Google Scholar
• Slater, P., Doyle, C. A., & Denkin, J. F. (1998). Abnormal persistence of cerebellar serotonin-1A receptors in schizophrenia suggests failure to regress in neonates. Jour-nal of Neural Transmission, 105, 305–315.
   PubMed Web of Science ®Google Scholar
• Sokoloff, P., Giros, B., Martres, M-P., Bouthenet, M-L., & Schwartz, J-C. (1990). Molec-ular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics.
   Google Scholar
• Spitzer, T. R., Grunberg, S. M., & Dicato, M. A. (1998). Antiemetic strategies for high dose chemoradiotherapy-induced nausea and vomiting. Supportive Care in Cancel; 6, 233-236. Nature, 347, 146–151.
   Google Scholar
• Stahl, S. M. (1998). Basic psychopharmacology of antidepressants. Part I. Antidepres-sants have seven distinct mechanisms of action. Journal of Clinical Psychiatry, 59\(Suppl. 4), 5–14.
   Google Scholar
• Starr, C. (1998). Emerging migraine treatments. Patient Care Nurse Practitioner, 1, 10–26.
   Google Scholar
• Suzdak, P. D., & Jansen, J. A. (1995). A review of the preclinical pharmacology of tiagabine: A potent and selective anticonvulsant GABA uptake inhibitor. Epilepsia, 36, 612–626.
   PubMed Web of Science ®Google Scholar
• Syvalahti, E. K. G. (1994). Biological factors in schizophrenia: Structural and functional aspects. British Journal of Psychiatry, /64\(Suppl. 23), 9–14.
   Google Scholar
• Taubes, G. (1994). Will new dopamine receptors offer a key to schizophrenia? Science, 265, 1034–1035.
   Google Scholar
• van Praag, H. M., Kahn, R. S., & Asnis, G. M., et al. (1987). Denosologization of biological psychiatry or the specificity of 5-HT disturbances in psychiatric disorders. Journal of Affective Disorders, 13, 1–8.
   Google Scholar
• Waldinger, M. D., Berendsen, H. H., Blok, B. F., Olivier, B., & Holstege, G. (1998). Premature ejaculation and serotonergic antidepressant-induced delayed ejaculation: The involvement of the serotonergic system. Behavioural Brain Research, 92, 111–118.
   PubMed Web of Science ®Google Scholar
• Willner, P. (1985). Antidepressants and serotonergic neurotransmission: An integrative review. Psychophannacology, 85, 387–404.
   PubMed Web of Science ®Google Scholar
• Zorumski, C. G., & Isenberg, K. E. (1991). Insights into the structure and function of GABA-benzodiazepine receptors: Ion channels and psychiatry. American Journal of Psychiatry, 148, 162–173.
   PubMedGoogle Scholar